PMID- 24018850
OWN - NLM
STAT- MEDLINE
DCOM- 20140611
LR  - 20221109
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 143
DP  - 2013
TI  - The expression of hypoxia-inducible factor-1alpha and its clinical significance in 
      lung cancer: a systematic review and meta-analysis.
PG  - w13855
LID - 10.4414/smw.2013.13855 [doi]
AB  - BACKGROUND: Hypoxia-inducible factor-1alpha (HIF-1alpha) plays an important role in 
      tumour progression and metastasis through activation of many target genes that 
      are especially involved in pivotal aspects of cancer biology. However, the 
      prognostic role of HIF-1alpha has been controversial in primary patients with lung 
      cancer. This meta-analysis was performed to systematically evaluate whether 
      HIF-1alpha expression is associated with the clinical outcomes in lung cancer 
      patients. METHODS: We retrieved relevant articles from Cochrane library, PubMed, 
      EMbase, CNKI, CBM, VIP and Wan Fang Databases from inception to May 2012. Studies 
      were selected using specific inclusion and exclusion criteria. A systematic 
      review and meta-analysis was performed on the association between HIF-1alpha 
      expression and clinical outcomes in lung cancer patients. All analyses were 
      performed using the Revman 5.1 software. RESULTS: A total of 30 studies were 
      identified as eligible for the systematic review and meta-analysis. The 
      expression of HIF-1alpha was significantly higher than those in normal lung tissue; 
      and III-IV stage, lymph node metastasis, poorly differentiation, squamous cell 
      carcinoma and small cell lung cancer (SCLC) were significantly higher than those 
      in I-II stage, no lymph node metastasis, well differentiation, adenocarcinomas 
      and non small cell lung cancer (NSCLC), respectively (odds ratio (OR) = 19.00, 
      95% confidence interval (CI):12.12-29.78, p <0.00001; OR = 0.23, 95% 
      CI:0.14-0.36, p <0.00001; OR = 3.72, 95% CI:2.38-5.80, p <0.00001; OR = 0.47, 95% 
      CI:0.31-0.70, p <0.00002, OR = 0.24, 95% CI:0.07-0.77, p = 0.02; OR = 0.78, 95% 
      CI:0.63-0.98, p = 0.03). VEGF and CA IX positive expression in HIF-1alpha positive 
      tumour tissues were significantly higher than those in HIF-1alpha negative tumour 
      tissues, respectively (OR = 3.23, 95% CI: 1.90-5.46, p <0.0001; OR = 3.84, 95% 
      CI: 2.10-7.03, p <0.0001). The positive HIF-1alpha tumour tissues of patients had 
      lower 5-year survival rates (OR = 0.13, 95% CI: 0.03-0.47, p = 0.002) and overall 
      survival (relative risk (RR) = 1.68, 95% CI: 1.12-2.50, p = 0.01). CONCLUSIONS: 
      HIF-1alpha is related to a differing degree of lung cancer cell, lymph node 
      metastasis, post-operative survival time and histology (NSCLC vs. SCLC, 
      adenocarcinomas vs. squamous cell carcinoma). HIF-1 alpha , which combines other 
      proteins, such as vascular endothelial growth factor (VEGF) or CA IX, might serve 
      as important parameters in evaluating biological behaviour and prognosis of lung 
      cancer; it will be of benefit to clinical treatment and prognostic evaluation.
FAU - Ren, Weiwei
AU  - Ren W
AD  - Evidence-Based Medicine Center of Lanzhou University, Gansu, CHINA; 
      renweiwei312@163.com.
FAU - Mi, Denghai
AU  - Mi D
FAU - Yang, Kehu
AU  - Yang K
FAU - Cao, Nong
AU  - Cao N
FAU - Tian, Jinhui
AU  - Tian J
FAU - Li, Zheng
AU  - Li Z
FAU - Ma, Bin
AU  - Ma B
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130906
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adenocarcinoma/*metabolism/mortality/pathology
MH  - Carcinoma, Non-Small-Cell Lung/metabolism/mortality/pathology
MH  - Carcinoma, Squamous Cell/*metabolism/mortality/pathology
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
MH  - Lung Neoplasms/*metabolism/mortality/pathology
MH  - Lymphatic Metastasis
MH  - Odds Ratio
MH  - Prognosis
MH  - Small Cell Lung Carcinoma/*metabolism/mortality/pathology
MH  - Survival Rate
MH  - Vascular Endothelial Growth Factor A/metabolism
EDAT- 2013/09/11 06:00
MHDA- 2014/06/12 06:00
CRDT- 2013/09/11 06:00
PHST- 2013/09/11 06:00 [entrez]
PHST- 2013/09/11 06:00 [pubmed]
PHST- 2014/06/12 06:00 [medline]
AID - smw-13855 [pii]
AID - 10.4414/smw.2013.13855 [doi]
PST - epublish
SO  - Swiss Med Wkly. 2013 Sep 6;143:w13855. doi: 10.4414/smw.2013.13855. eCollection 
      2013.